Ongoing Clinical Studies

Title PI / Site PI Agency
BRAVOS: Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study Mayes (NIH/NIAID)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Sclerosis Mayes Mitsubishi Tanabe Pharma Development America, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients with Diffuse Cutaneous Systemic Sclerosis Mayes Horizon Therapeutics U.S.A., Inc.
Classification of Axial Spondyloarthritis Inception Cohort (CLASSIC) Reveille Spondyloarthritis Research and Treatment Network (SPARTAN)
A Multicenter, Long-Term Extension Study of 104 Weeks, including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal – Retreatment Period, to Evaluate the Maintenance of treatment Effect of Ixekizumab in Patients with Axial Spondyloarthritis Reveille Lilly USA, LLC
Individualizing Anti-Inflammatory Medications for Adults with Axial Spondyloarthritis: A Series of N-of 1 Trials Hwang NIH